SS-GCC1- Screening Study of Genetic Changes in Colorectal Cancer
All patients at the Royal Marsden with a diagnosis of colorectal cancer will be eligible to
enter this study. This will include patients both with early and advanced disease, provided
they give informed consent. They will give written consent to participate, to include
consent for analysis of existing tumour tissue and consent for collection of demographic and
clinicopathological data relating to their case and its future outcome, and consent for a
blood sample to be taken for research purposes. Additionally, old samples of material
surplus to clinical requirements may be collected without specific consent if there is no
possibility that it would affect the patient's interest (eg the patient has died).
Observational Model: Cohort, Time Perspective: Prospective
the primary endpoint is the identification of cases with evidence of loss of the product of one of the four main MMR genes on tumour histology.
Prof Cunningham, David
Royal Marsden NHS Foundation Trust
United Kingdom: Research Ethics Committee